Orchid Pharma to transfer NPNC formulations division to JV with Bionpharma
Chennai: Orchid Pharma Ltd has recently announced that its Non-Penicillin, Non-Cephalosporin (NPNC) formulations division would be moved to a new joint venture with a subsidiary of Bionpharma, a US-based generic pharmaceuticals firm.
Orchid Pharma Limited has signed a Binding Term Sheet on May 05, 2021, for the transfer of its non-penicillin, non-cephalosporin (NPNC) Formulations Division (IKKT Undertaking) at Irungattukottai, Chennai to a Joint Venture with a subsidiary of Biopharma, a US-based generic pharmaceutical company with a commercial portfolio and a pipeline of generic products in the United States.
As a part of this strategic collaboration, the Company has informed that it will transfer its IKKT Undertaking to a "New Company" to be incorporated as a 74:26 Joint Venture with this Bionpharma entity. The consideration for the transaction is estimated to be up to Rs.170 Crores in a combination of cash and equity stake in the Joint Venture Company.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.